Back
Sirtex

SIR-Spheres

Resin microspheres Y-90 indicated for radioembolization treatment in unresectable Hepatocellular Carcinoma (HCC) and Primary Colorectal Cancer (mCRC) in patients refractory or intolerant to chemotherapy, through the Selective Internal Radiotherapy Technique (SIRT).

* Product sold exclusively in part of the national area (Spain).

Details of the product

The main features of the SIR-Spheres Y-90 are:

  • Permanent single-use implant: It is used once to treat liver tumors.
  • Uniform radiation distribution: The high number of microspheres ensures a homogeneous distribution of radiation, allowing the treatment of solitary and multifocal tumors.
  • Specific density similar to red blood cells: Which allows them to be transported by the bloodstream and penetrate the tumor microvasculature.
  • Controlled administration: Microspheres can be delivered slowly to maximize the amount administered and improve tumor coverage.
  • Yttrium-90: Radioisotope with two safety features: minimal beta radiation penetration and a short half-life of 64.1 hours, which reduces the risk to staff and patients.

 

Technical Specifications

PRODUCT SPECIFICATIONS
Isotope Ytro-90 (Y-90)
Degradation product Zirconium-90
Composition of the spheres Resin
Specific density 1.125 g / ml
Diameter 32,5 μm ± 2.5 μm (range 20-60 microns)
T1 / 2 64.1 h (95% disintegrates in 11 days)
β-energy (max.) 2.27 MeV (Iβ = 100%)
Activity-dose conversion factor 49.67 Gy/ (GBq x Kg)
Penetration 2,5 mm (medium), up to 11 mm
Radioactivity/microsphere 68 Bq ± 10% at calibration date and time
Introduction Single dose size containing 3,0 GBq ± 10% Y-90 at the date and time of calibration in 5 ml water for injection, wet-sterilized
Number of microspheres per vial 44,5 million
MANAGEMENT FEATURES
Administration mode Directed, slow and controlled flow with complete visibility
Flexibility The shipping vial can be divided into multiple treatment vials for a single patient with multiple injection sites.

Order information